CARDIFF ONCOLOGY, INC. Proceeds from Long-term Lines of Credit
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Long-term Lines of Credit of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2018-02-26
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for the quarter ending 2017-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for the quarter ending 2017-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for fiscal 2016 was $792.25K, a 27.05% decline from fiscal 2015.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for fiscal 2015 was $1.09M.
- CARDIFF ONCOLOGY, INC. proceeds from long-term lines of credit for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $0.00 derived: sum of 3 quarters · filed 2018-02-26 | $0.00 10-K · filed 2018-02-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | $0.00 derived: sum of 4 quarters · filed 2018-02-26 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | $0.00 derived: sum of 3 quarters · filed 2018-02-26 | $0.00 derived: sum of 4 quarters · filed 2018-02-26 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $0.00 derived: sum of 3 quarters · filed 2018-02-26 | $241.95K derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $241.95K derived: sum of 3 quarters · filed 2018-02-26 | $792.25K 10-K · filed 2018-02-26 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $241.95K derived: sum of 2 quarters · filed 2017-11-09 | $792.25K 10-Q · filed 2017-11-09 | $1.88M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $241.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $792.25K 10-Q · filed 2017-08-09 | $1.88M derived: sum of 3 quarters · filed 2017-08-09 | $1.88M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $550.30K 10-Q · filed 2017-05-10 | $1.64M derived: sum of 2 quarters · filed 2017-05-10 | $1.64M derived: sum of 3 quarters · filed 2017-05-10 | $1.64M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.09M derived: sum of 2 quarters · filed 2017-03-15 | $1.09M derived: sum of 3 quarters · filed 2017-03-15 | $1.09M 10-K · filed 2017-03-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-10 | |||
| 2013-12-31 | $515.96K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |